BNP Paribas Financial Markets
URGN icon

BNP Paribas Financial Markets’s UroGen Pharma URGN Stock Holding History

BNP Paribas Financial Markets’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Buy
43,599
+34,079
+358% +$924K ﹤0.01% 2984
2026
Q1 		$171K Buy
9,520
+274
+3% +$5.49K ﹤0.01% 4121
2025
Q4 		$217K Sell
9,246
-299,082
-97% -$6.49M ﹤0.01% 4019
2025
Q3 		$6.15M Buy
308,328
+236,407
+329% +$4.25M ﹤0.01% 1850
2025
Q2 		$985K Buy
71,921
+69,503
+2,874% +$667K ﹤0.01% 2918
2025
Q1 		$26.7K Sell
2,418
-2,383
-50% -$25.4K ﹤0.01% 4458
2024
Q4 		$51.1K Sell
4,801
-3,745
-44% -$44.8K ﹤0.01% 4421
2024
Q3 		$109K Buy
8,546
+5,890
+222% +$87.4K ﹤0.01% 3435
2024
Q2 		$44.6K Sell
2,656
-37,139
-93% -$528K ﹤0.01% 3472
2024
Q1 		$597K Buy
39,795
+16,799
+73% +$275K ﹤0.01% 2755
2023
Q4 		$345K Buy
22,996
+6,617
+40% +$85.9K ﹤0.01% 3001
2023
Q3 		$229K Buy
16,379
+11,277
+221% +$181K ﹤0.01% 3043
2023
Q2 		$52.8K Buy
5,102
+4,925
+2,782% +$54.3K ﹤0.01% 3455
2023
Q1 		$1.64K Sell
177
-1,104
-86% -$10.2K ﹤0.01% 3649
2022
Q4 		$11.4K Sell
1,281
-50
-4% -$474 ﹤0.01% 3600
2022
Q3 		$11.1K Sell
1,331
-6,249
-82% -$51.7K ﹤0.01% 4171
2022
Q2 		$62.1K Buy
7,580
+5,881
+346% +$40.4K ﹤0.01% 3504
2022
Q1 		$14.8K Sell
1,699
-2,794
-62% -$21.8K ﹤0.01% 3758
2021
Q4 		$42.7K Buy
4,493
+934
+26% +$13.2K ﹤0.01% 3765
2021
Q3 		$59.9K Buy
3,559
+2,785
+360% +$44.1K ﹤0.01% 3462
2021
Q2 		$11.8K Sell
774
-3,665
-83% -$66.3K ﹤0.01% 3683
2021
Q1 		$86.5K Buy
4,439
+657
+17% +$13.9K ﹤0.01% 3413
2020
Q4 		$68.2K Sell
3,782
-806
-18% -$16.9K ﹤0.01% 3410
2020
Q3 		$88.5K Buy
4,588
+3,521
+330% +$79.7K ﹤0.01% 3185
2020
Q2 		$27.9K Sell
1,067
-5,031
-83% -$123K ﹤0.01% 3263
2020
Q1 		$109K Buy
6,098
+3,605
+145% +$97.4K ﹤0.01% 3157
2019
Q4 		$83.2K Sell
2,493
-866
-26% -$23.6K ﹤0.01% 3368
2019
Q3 		$80K Buy
+3,359
New +$110K ﹤0.01% 3238

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

BNP Paribas Financial Markets's URGN Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its UroGen Pharma (URGN) stake by 358% in Q2 2026, buying an estimated $924K and bringing the position to 43,599 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2984.

BNP Paribas Financial Markets first reported a position in URGN in Q3 2019 and has held it in 28 quarters since. The position peaked at $6.15M in Q3 2025. 174 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • BNP Paribas Financial Markets held 43,599 shares of UroGen Pharma worth $1.6M as of Q2 2026.
  • BNP Paribas Financial Markets bought 34,079 UroGen Pharma shares in Q2 2026, an estimated $924K.
  • UroGen Pharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2984 holding.
  • BNP Paribas Financial Markets first reported a position in UroGen Pharma in Q3 2019 and has held it in 28 quarters since.
  • BNP Paribas Financial Markets's UroGen Pharma position peaked at $6.15M in Q3 2025.
  • 174 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.